Cagrilintide
Cagrilintide (long-acting amylin analogue)
What is Cagrilintide?
Cagrilintide: Long-acting once-weekly amylin analogue (amylin/calcitonin receptor agonist) from Novo Nordisk that reduces appetite. The sources cited here most often discuss it for: Weight loss; Bigger results with semaglutide; Quieter food noise. Evidence label: Trial-backed.
- Type
- Peptide
- Family
- Weight & Metabolic
- Evidence label
- Trial-backed (4 of 5)
- Regulatory status
- CagriSema (cagrilintide plus semaglutide) is not FDA-approved; Novo Nordisk submitted its application in December 2025, and the company expects an FDA decision in the fourth quarter of 2026.
- Goals discussed
- Fat Loss & Metabolism, Calm & Mood
- Also called
- AM833, NN 9838, NNC-0174-0833, Cag, Cagri
- Last reviewed
- 2026-10-11
- Long-acting once-weekly amylin analogue (amylin/calcitonin receptor agonist) from Novo Nordisk that reduces appetite; investigational, not FDA-approved alone; combo with semaglutide (CagriSema) filed with FDA Dec 2025, decision expected Q4 2026. )01751-7/abstract12
Most large trial results, including the REDEFINE program, are for CagriSema, a fixed combination of cagrilintide with semaglutide, not cagrilintide alone.
Regulatory status CagriSema (cagrilintide plus semaglutide) is not FDA-approved; Novo Nordisk submitted its application in December 2025, and the company expects an FDA decision in the fourth quarter of 2026. 3
Names as used in gyms, forums and gray-market listings. Reported, not endorsed; stacks have not been studied as combinations.
Treatment with cagrilintide in people with overweight and obesity led to significant reductions in bodyweight and was well tolerated.
26-week phase 2 dose-finding RCT of cagrilintide alone in 706 adults (cagrilintide, liraglutide and placebo arms), funded by Novo Nordisk.
What is Cagrilintide researched for?
The three outcomes most discussed for Cagrilintide in the sources below, as those sources report them. humanpeptides.fyi makes no claims of its own: a listed benefit can be unproven or can have failed in trials, and the label on each line says which.
What do researchers and users say about Cagrilintide?
after 52 weeks, across all measures of appetite and eating behaviour, people with overweight and obesity had substantially reduced food cravings and sustained changes in the brain response to viewing pictures of high-calorie foods
Comment in Novo Nordisk's EASD 2026 announcement of a 52-week brain-scan study of CagriSema (cagrilintide + semaglutide); not yet peer reviewed.
For me it has been the first peptide to absolutely smoke my hunger.
User report in a cagrilintide experience thread; the user was also taking retatrutide.
What side effects of Cagrilintide are reported?
- Nausea and other GI effects, dose-escalation dependent; 10.3% discontinued in phase 2; CagriSema GI events in 79.6%, mostly mild-moderate and transient (human RCTs) )01751-7/abstract15
- Fatigue commonly reported by usersanecdotal10
- Injection-site (administration-site) reactions were among the most frequent adverse events with cagrilintide alonehuman RCT9
- With CagriSema in REDEFINE 1: nausea 55%, constipation 30.7% and vomiting 26.1%, versus 12.6%, 11.6% and 4.1% with placebohuman RCT, company release11
- Users describe feeling flat, unmotivated or weakanecdotal10
- Small heart-rate increases, and rare pancreatitis or gallbladder problems, flagged as possible concerns shared with other weight-loss drugstheoretical, education site12
What do peptide guides say about Cagrilintide?
- PepEdHub PepEdHub explains that cagrilintide activates amylin receptors in the brain's area postrema to reduce appetite, slow stomach emptying and suppress glucagon, complementing semaglutide in the CagriSema combination. 13
- Seek Peptides Seek Peptides flags fatigue, affecting roughly one in five phase 2 participants by its account, as an overlooked side effect, and lists open questions about long-term gallbladder, antibody and bone effects. 12
- NCBI PMC In obese mice, cagrilintide's weight loss depended on brain amylin receptors AMY1 and AMY3; mice lacking the RAMP1 and RAMP3 receptor components responded less. 14
- BioPharma Dive In an 84-week head-to-head phase 3 trial, CagriSema produced about 20% average weight loss versus about 24% with Lilly's Zepbound, too large a gap to declare it non-inferior. 15
What does the research say, system by system?
Body & tissues1
- CagriSema reported benefits in organ and bone health at EASD 2026 (company release)7
Hormones & physiology2
Brain, mood & sleep1
- Acts on brain appetite centres; reduced food noisehuman trial, company release7
Weight & metabolism1
Muscle1
- In REDEFINE 1, fat-mass loss predominated over lean masshuman RCT body composition substudy5
Also notable1
- Grey-market 'research' cagrilintide widely used on Reddit, often stacked with retatrutide/semaglutideanecdotal17
How strong is the evidence for Cagrilintide?
Strong human RCT data (phase 2 alone, phase 3 with semaglutide); not yet FDA-approved
Larger randomized human trials exist, positive or negative, but no US approval for the uses discussed. How tiers work
Questions about Cagrilintide
What is Cagrilintide?
Long-acting once-weekly amylin analogue (amylin/calcitonin receptor agonist) from Novo Nordisk that reduces appetite. Most large trial results, including the REDEFINE program, are for CagriSema, a fixed combination of cagrilintide with semaglutide, not cagrilintide alone.
Is Cagrilintide FDA-approved?
CagriSema (cagrilintide plus semaglutide) is not FDA-approved; Novo Nordisk submitted its application in December 2025, and the company expects an FDA decision in the fourth quarter of 2026.
What is Cagrilintide researched for?
The sources cited on this page most often discuss three outcomes: Weight loss; Bigger results with semaglutide; Quieter food noise. Each line above shows what the source reports and how strong that evidence is.
What side effects of Cagrilintide are reported?
Reported in the cited sources: Nausea and other GI effects, dose-escalation dependent; 10.3% discontinued in phase 2; CagriSema GI events in 79.6%, mostly mild-moderate and transient (human RCTs) )01751-7/abstract; Fatigue commonly reported by users; Injection-site (administration-site) reactions were among the most frequent adverse events with cagrilintide alone. The list is not complete, and few listed risks does not mean a compound is safe.
How strong is the evidence for Cagrilintide?
Evidence label: Trial-backed. Strong human RCT data (phase 2 alone, phase 3 with semaglutide); not yet FDA-approved.
What else is Cagrilintide called?
Names used for it include AM833, NN 9838, NNC-0174-0833, Cag, Cagri.
Does humanpeptides.fyi recommend Cagrilintide?
No. humanpeptides.fyi makes no claims and no recommendations of its own. It summarizes and links to what others have published and posted. Nothing here is medical advice; talk to a licensed clinician.